Abiraterone acetate

Drugs R D. 2010;10(4):261-9. doi: 10.2165/11587960-000000000-00000.

Abstract

Abiraterone acetate (CB 7630; CB7630; JNJ-212082), the 3β-acetate prodrug of abiraterone, is structurally related to ketoconazole and is being developed by Cougar Biotechnology as a hormonal therapy for advanced prostate and breast cancers. As a selective inhibitor of adrenal androgens, it is thought to be a safer product than existing second-line hormonal therapies. This review discusses the key development milestones and therapeutic trials of this drug.

Publication types

  • Review

MeSH terms

  • Abiraterone Acetate
  • Androgen Antagonists / pharmacology
  • Androgen Antagonists / therapeutic use*
  • Androstadienes / pharmacology*
  • Androstadienes / therapeutic use*
  • Animals
  • Antineoplastic Agents, Hormonal / pharmacology
  • Antineoplastic Agents, Hormonal / therapeutic use*
  • Drug Evaluation, Preclinical
  • Drugs, Investigational / pharmacology
  • Drugs, Investigational / therapeutic use*
  • Humans
  • Neoplasms / drug therapy*
  • Prodrugs / pharmacology
  • Prodrugs / therapeutic use*

Substances

  • Androgen Antagonists
  • Androstadienes
  • Antineoplastic Agents, Hormonal
  • Drugs, Investigational
  • Prodrugs
  • Abiraterone Acetate